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PROTOCOL: INTRACAMERAL CEFUROXIME FOR PROPHYLAXIS OF ENDOPHTHALMITIS FOLLOWING 





PURPOSE:  Did the introduction of intracameral cefuroxime during cataract surgery reduce the rate 
of endophthalmitis in a hospital in South Africa? Did the results of the ESCRS study influence South 
African ophthalmologists, and what percentage use intracameral cefuroxime? 
SETTING: Groote Schuur Hospital, Cape Town, South Africa. 
DESIGN: Before-after retrospective case series, cross sectional survey 
METHODS:  Data will be collected over a six year period, examining all reported cases of 
endophthalmitis following cataract surgery and comparing the data for the three years prior to the 
introduction of cefuroxime, to the three years after the introduction of cefuroxime. A questionnaire, 
with an enclosed self-addressed envelope, will be mailed to all South African ophthalmologists. 
RESULTS: Data will be analysed using the statistical program Stata Version 9.0. Variables will be 
described using means, medians, and proportions, as appropriate. Bivariate comparisons will be 
based on student t test (for means), Wilcoxon sum rank test (for medians), and Chi square or Fisher’s 
exact test (for proportions). 
 CONCLUSION:  A paper reporting the findings will be submitted to a peer reviewed journal for 
























Endophthalmitis remains one of the most devastating complications following cataract surgery, and 
the prognosis and successful treatment depends on timely and appropriate management, as 
demonstrated in the Endophthalmitis Vitrectomy Study.1,2 
 
Because the treatment of endophthalmitis can be extremely problematic in low and middle income 
countries where patients often present late and access to vitreoretinal services are limited, 
preventing the infection altogether is of utmost importance.  
 
According to a 2006 survey in the United Kingdom among 800 consultant ophthalmologists, 
prophylactic measures varied widely, with only 13.6% of patients receiving intracameral antibiotics 
and 4.1% antibiotic infusions.3  
 
The European Society of Cataract and Refractive Surgeons (ESCRS) recognized the need to 
investigate the use of antimicrobial prophylaxis. According to the findings of a prospective 
randomized study (announced in 2006) published in 2007, the absence of an intracameral 
cefuroxime prophylactic antibiotic was associated with a 4.92-fold increase in the risk for total 
postoperative endophthalmitis.4 This is the first prophylactic anti-infective regimen to be proven 
effective by a prospective randomized controlled study.5 Believing the results conclusive, the study 
was terminated prematurely and the routine use of intracameral cefuroxime recommended. 
 
In January 2007 an online survey was conducted among the approximately 4000 members of the 
American Society of Cataract and Refractive Surgeons (ASCRS). Surprisingly 77% of surgeons still did 
not use intracameral cefuroxime and did not plan to use it in the near future.5 Almost 90% of the 
surgeons felt that further study was needed and 45% were concerned about the risk involved. 
 
Further studies have confirmed the efficacy of intracameral cefuroxime in preventing 
endophthalmitis, without any significant adverse effects.6-9 . Following the publication of the results 
of the ESCRS study, intraoperative intracameral cefuroxime was introduced as our standard practice 
at Groote Schuur Hospital in August 2006. 
 
Apart from patients with known cefuroxime hypersensitivity, all patients routinely receive 1mg of 














This study is to evaluate: 
 1. Whether the routine use of intracameral cefuroxime results in a decrease in the incidence of 
endophthalmitis in our setting.       
 
2. The trend of endophthalmitis prophylaxis among South African ophthalmologists.    
 
   
Objective 
RESEARCH QUESTIONS: 
 1: Does the use of intraoperative intracameral cefuroxime reduce the risk of post-operative 
endophthalmitis at Groote Schuur Hospital? 
 
 2: Do South African ophthalmologists use intracameral cefuroxime for endophthalmitis prophylaxis 






1: A descriptive and analytical retrospective case series. 
 




Data will be collected from : 













1.2: All patients who had cataract surgery in the 36 month period after the introduction of 
cefuroxime prophylaxis. 
 
2: All ophthalmologists in South Africa will be surveyed, using the questionnaire in appendix two, via 
mail with a self-addressed envelope included.  
 
Measurement 
1. For the descriptive and analytical retrospective case series the following data will be collected: 
Number of cataract surgeries performed. 
Whether  the patient received cefuroxime. 
Number of patients admitted for presumed endophthalmitis. 
Number of culture proven cases of endophthalmitis. 
Number of patients receiving intravitreal antibiotics. 
Number of patients requiring pars plana vitrectomy. 
 Visual outcome post endophthalmitis treatment. 
 Associated possible risk factors in endophthalmitis cases, including gender, age, race, type of 
surgery, surgeon experience i.e. consultant/registrar/medical officer, surgical complications and 
other ocular pathology.   
 The number of cataract surgeries done will be obtained from theatre records. 
 The admission records of endophthalmitis cases will be obtained from the clinicom records, 
specifying the number of admissions for code H44.0 between August 2003 and July 2009. 
 A separate data collection form will be completed for all patients who presented to the 
ophthalmology ward with suspected endophthalmitis. 
 
2. For the cross sectional survey of all South African ophthalmologists the data will be collected as 
follows: 
All ophthalmologists will be contacted via mail to their registered private practice address and asked 





Data will be analysed using the statistical program Stata Version 9.0. Variables will be described 
using means, medians, and proportions, as appropriate. Bivariate comparisons will be based on 
student t test (for means), Wilcoxon sum rank test (for medians), and Chi square or Fisher’s exact 












The main analysis will focus on: 
1:The difference in the incidence of endophthalmitis in the patients having cataract surgery before 
August 2006 and not receiving intracameral cefuroxime, and in the patients having cataract surgery 
after August 2006 and receiving intracameral cefuroxime. 
 
2: The proportion of South African ophthalmologists using intracameral cefuroxime for 
endophthalmitis prophylaxis. 




 ETHICS AND COMMUNICATION 
 Ethics 
Ethical approval will be obtained from the University of Cape Town Faculty of Health Sciences ethics 
committee. 
 
Reporting and implementation 
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Appendix one: Patients with endophthalmitis- data collection form. 
 .                                             
Code 
Name   
Hospital number   
Age   
Race   
Gender   
Date of surgery   
Type of surgery      
Surgeon experience   
Surgical complications   
If yes to above, specify briefly   
Intracameral cefuroxime   
Other ocular pathology   
If yes to above, specify briefly   
Date of admission for presumed 
endophthalmitis 
  
Culture positive   
Specify organism   
Administration of intravitreal 
antibiotics 
  
Specify type of antibiotic   
Pars plana vitrectomy   















Appendix two: survey of endophthalmitis prophylaxis. 
DIVISION OF OPHTHALMOLOGY, GROOTE SCHUUR HOSPITAL: SURVEY OF ENDOPHTHALMITIS 
PROPHYLAXIS IN CATARACT SURGERY IN SOUTH AFRICA 
PLEASE INDICATE WHICH OF THE FOLLOWING PERIOPERATIVE MEASURES ARE USED BY YOU 
DURING CATARACT SURGERY.  
NAME (FOR STATISTICAL PURPOSES ONLY, YOUR ANSWERS WILL BE ANONYMOUS)  
__________________________________________________ 
1. INTRACAMERAL CEFUROXIME                                                               
  
2. INTRACAMERAL MOXIFLOXACIN   
 
3. INTRACAMERAL VANCOMYCIN   
 
4. VANCOMYCIN ADDED TO IRRIGATION FLUID 
 
5. SUBCONJUNCTIVAL GENTAMICIN   
 
6. SUBCONJUNCTIVAL CEFUROXIME   
 
7. TOPICAL MOXIFLOXACIN (VIGAMOX) 
 
8. OTHER(PLEASE SPECIFY)____________________________________       
THANK YOU. 
 
DR JUNET VAN DER MERWE: Registrar, Department Ophthalmology, 
Groote Schuur Hospital, 















 Appendix three: coding form. 
 
 
.        
                                     Code 
Name  
Hospital number  
Age Age in years 
Race 
 
White : 1                                  
 Black:  2                                 Asian: 4 
Coloured: 3                            Unspecified: 5 
Gender Male: 1 
Female: 2 
Date of surgery  
Type of surgery 
 
Phacoemulsification: 1 
Extracapsular cataract extraction :2 
Unspecified: 3  
Surgeon experience Consultant: 1                             Junior registrar: 3 
Senior registrar: 2                     Medical officer: 4  
Surgical complications Yes: 1 
No: 2 
If yes to above, specify briefly Posterior capsule tear: 1            Phaco-conversion: 5 
Vitrectomy: 2                               Iris damage: 6 
Dropped lens/ fragment: 3        Zonular dehiscence: 7 
Aphakic: 4                                     Unspecified: 8 
Intracameral cefuroxime Yes: 1 
No: 2 
Other ocular pathology Yes: 1 
No: 2 
If yes to above, specify briefly Diabetes: 1                                 Previous trauma: 7 
Glaucoma: 2                               Previous uveitis: 8 
Corneal opacity: 3                     Retinal detachment: 9 
Corneal guttatae: 4                   Previous ocular surgery: 10 
Blepharitis: 5                              Ocular surface disease: 11 
Pseudoexfoliation: 6                 Unspecified: 12 
Date of admission for presumed 
Endophthalmitis 
 













Specify organism Gram negative bacilli: 1             Filamentous bacteria: 5 
Gram positive bacilli: 2              Mycobacteria: 6 
Gram negative cocci: 3               Fungal: 7 
Gram positive cocci: 4                Unspecified: 8 




Specify type of antibiotic Ceftazidime plus Vancomycin: 1                            
Other: 2 
Pars plana vitrectomy Yes: 1 
No: 2 
Final visual acuity 
 
6/6 or better: 1 
6/7.5 - 6/18: 2 
6/24 – 6/60: 3 
Count fingers: 4 
Hand movement: 5 
Perception of light: 6 









































Endophthalmitis remains one of the most devastating complications following cataract surgery, and 
the prognosis and successful treatment depends on timely and appropriate management, as 
demonstrated in the Endophthalmitis Vitrectomy Study.1The treatment of endophthalmitis can be 
extremely problematic in low and middle income countries where patients often present late and 
access to vitreoretinal services are limited. Preventing endophthalmitis is therefore important.    
 
The optimal regime for endophthalmitis prophylaxis remains a controversial issue. Endophthalmitis 
fortunately is a rare occurrence but this makes it difficult to conduct adequately powered studies.2,3 
The incidence of presumed infectious endophthalmitis is low, with reported rates of 0.05% to 0.36% 
and an overall estimate of 0.13%.4-6 
 
The only evidence based method of endophthalmitis prophylaxis shown to be effective in the past, 
was the use of povidone-iodine 5% in the conjunctival sac before surgery.7 
  
Many different techniques are being used without reliable scientific evidence. The incidence of 
endophthalmitis is so low, that a very large study is needed to provide statistically significant 
evidence to detect a reduction in the incidence of endophthalmitis.2,3 
 
Most surgeons use an antibiotic prophylactically. Some use vancomycin either in the irrigation fluid 
or by intracameral injection. This practice is not recommended because vancomycin is reserved for 
the treatment of methicillin-resistant Staphylococcus aureus (MRSA) endophthalmitis and other 
MRSA infections.8 Both the American Academy of Ophthalmology and the Center for Disease Control 

















RESULTS OF THE ESCRS MULTICENTER STUDY 
 
There existed a need to find scientific evidence for the most appropriate endophthalmitis regime. 
The European Society of Cataract and Refractive Surgeons (ESCRS) initiated a large scale, randomized 
partially masked prospective placebo-controlled multicenter study across Europe including Austria, 
Belgium, Germany, Italy, Poland, Portugal, Spain, Turkey and the United Kingdom. 
 
The main objective of the study was to determine whether a perioperative antibiotic helps prevent 
subsequent endophthalmitis and additionally to collect data which would be helpful in identifying 
risk factors for endophthalmitis. In this study two drugs were chosen for the trials. Cefuroxime was 
chosen for intracameral use because of the Swedish study in which efficacy and safety was 
established.9,10 Levofloxacin, a third –generation fluoroquinolone was chosen because it is well 
absorbed into the anterior chamber 11 and showed enhanced anti-bacterial activity compared to 
ciprofloxacin and ofloxacin.  
 
Patient recruitment was started in September 2003. There were 16 603 patients recruited, 324 were 
lost to follow-up and 68 were omitted because they did not have the planned surgery or withdrew 
their consent.12 The study was scheduled to continue recruiting patients until 31 March 2006, but 
was terminated early in January 2006 after it became clear that intracameral cefuroxime reduced 
the risk to approximately one-fifth the value observed without prophylaxis.13 
 
The patients were recruited into one of four groups. Group A received placebo vehicle drops x five 
and no intracameral injection. Group B received placebo vehicle drops x five and intracameral 
cefuroxime. Group C received levofloxacin drops 0.5% x five and no intracameral cefuroxime. Group 
D received levofloxacin drops 0.5% x five and intracameral cefuroxime. 
 
The incidence of endophthalmitis was highest in group A where the total rate was 0.345%, and for 
proven endophthalmitis 0.247%. The lowest incidence was in group D with a rate of 0.049% for total 
endophthalmitis and 0.025% for proven endophthalmitis.12 
 
In group B the total rate was 0.074% and the proven rate was 0.049%, indicating that adding 
levofloxacin was not of major benefit. 
 
In the intent-to-treat patient population that received intracameral cefuroxime (Group B and D), the 
endophthalmitis rate was only 0.062%. The rate in the groups that did not receive cefuroxime 













The endpoint of the study was the diagnosis of endophthalmitis, but not all the cases identified as 
endophthalmitis had positive cultures. Endophthalmitis was diagnosed in 29 patients, 20 proven and 
nine unproven. The median time to presentation was 4.5 days. There was no case of early-onset 
(one-three days) endophthalmitis in the two groups that received intracameral cefuroxime. The 
early onset cases were associated with rapid and severe onset of symptoms. These cases included six 
isolates of streptococcal species and two isolates of Staphylococcus epidermidis.14 There were a total 
of eight proven streptococcal infections, all in the groups that did not receive cefuroxime, and five of 
the eight patients had a final visual acuity of 20/200 or worse.14 Streptococcal endophthalmitis 
resulted in earlier onset and worse outcomes than staphylococcal infections. This trend has also 
been demonstrated in other studies.15,16 
 
 
INTRACAMERAL ANTIBIOTICS: QUESTIONS IN THE UNITED STATES 
 
In January 2007, 4000 members of the American Society of Cataract and Refractive Surgery (ASCRS) 
were asked to participate in an online survey about endophthalmitis prophylaxis. A total of 1312 
members responded. The majority of respondents (69%) were from the United States.17  
 
Most surgeons used topical antibiotics, and fourth-generation fluoroquinolones were preferred by 
81%. Only 30% of respondents used intracameral antibiotics which included vancomycin, 
cephalosporins and quinolones. Vancomycin was used by 61% which is interesting because as 
mentioned earlier, the American Academy of Ophthalmology advises against it. 
 
The publication of the ESCRS study appeared not to have a significant impact on the respondents of 
the survey. Only 7% started or planned to use intracameral cefuroxime in the near future and 77% 
did not have any plans to use intracameral cefuroxime.17 A variety of reasons were stated for not 
using it. Most surgeons (89%) felt that further study was needed and 45% were concerned about the 
risks involved which might include dilution errors, or toxic anterior segment syndrome. However, 
80% would inject intracameral antibiotics if a commercially approved preparation were available at 
reasonable cost. 
 
The Mayo clinic published an article in 2008 highlighting the concerns in the United States regarding 
intracameral cefuroxime.18 The rate of endophthalmitis in the intracameral cefuroxime group in the 
ESCRS study were similar to rates reported in other studies in the U.S. where only topical antibiotics 













The authors felt that the actual benefit of cefuroxime may be less if compared with the 
perioperative use of topical antibiotics in the U.S. However, there are no large evidence based 
studies to prove this statement. The actual rate of endophthalmitis might be even less in the U.S. if 
cefuroxime were introduced.  
 
Another factor to be considered is the duration of protective effect from intracameral antibiotics. It 
is short, probably fewer than 24 hours. The risk of contamination from the surface of the eye is not 
addressed by the use of intracameral antibiotics. This risk remains until the wound heals.18 
 
The choice of cefuroxime was questioned as well. It has only average coverage of gram-positive and 
gram-negative organisms, does not cover MRSA, and has time dependent action, taking several 
hours to be effective, therefore dilution may occur before effectiveness.19,21 Despite the above 
concerns, cefuroxime has been proven to be effective and the concerns remain speculation until 
studies prove otherwise. 
 
Swedish ophthalmologists have a low rate of endophthalmitis and use intracameral antibiotics and 
not pre- or postoperative antibiotics. They also found that perioperative topical antibiotics had 
minimal or no additional benefit.22,23 
 
Almost all surgical specialities, except ophthalmology, have published joint guidelines for antibiotic 
prophylaxis of postsurgical infection.24 There are no large randomized controlled prospective studies 
evaluating the effectiveness of antibiotics in the irrigation fluid or topical antibiotics pre- and 
postoperatively. The only way to have consensus will be to launch a large cross-continental study to 
address all the issues raised. 
 
 
SAFETY PROFILE OF CEFUROXIME 
 
One of the most quoted reasons for not using cefuroxime is concerns about the safety profile. 
Numerous studies have been published evaluating the safety of cefuroxime. One of the first studies 
was done in Sweden at St. Eriks Hospital where cefuroxime was added to the prophylactic program 
in January 1996.10 Cefuroxime was evaluated in a nonrandomized observer-masked best-case trial. 
Cefuroxime did not have a statistically significant effect on endothelial cell loss, postoperative visual 
acuity or inflammation compared with non-administration of cefuroxime. Cefuroxime 












cataract patients. Therefore it is safe to conclude that IgE-dependent hypersensitivity to cefuroxime 
is very rare. 
 
Macular thickness after cataract surgery was evaluated in a prospective randomized double-masked 
clinical study in 2004.25 The study group received 1mg of intracameral cefuroxime and the control 
group received intracameral balanced salt solution (BSS). Twenty-three patients in the cefuroxime 
group and 17 patients in the BSS group had OCT performed four to six weeks postoperatively. 
Intracameral cefuroxime did not have a statistically significant effect on macular thickness. 
 
The dose dependent risk of cefuroxime and corneal endothelial cell death has also been evaluated.26 
Human corneal endothelial cells were exposed to various concentrations of cefuroxime and 
vancomycin. Reduction in cell viability was observed in concentrations higher than 2.75 mg/ml for 
cefuroxime and 5.0 mg/ml for vancomycin. The current cefuroxime dose of 1 mg diluted in 0.1 ml 
BSS results in a final concentration of nearly 2.75 mg/ml and no adverse effects were detectable at 
that dose. 
 
A randomized controlled trial on the safety of intracameral ce halosporins confirmed the above 
findings.27 A 1mg dose of intracameral cefuroxime, cefazolin and ceftazidime were evaluated in the 
randomized trial. Central endothelial cell density (ECD) and retinal centre point thickness (CPT) were 
measured before and three months after surgery. None of the cephalosporins had any significant 
effect on ECD or CPT.  
 
 
COMPLICATIONS ASSOCIATED WITH CEFUROXIME    
 
There are reports in the literature of complications associated with the use of intracameral 
cefuroxime. A severe anaphylactic reaction in a patient with known penicillin allergy has been 
reported. The patient recovered well after immediate resuscitation.28 
 
Dilution errors remain a potential risk factor. There are no commercially available preparations and 
the cefuroxime has to be diluted prior to theatre according to a dilution protocol so that the final 
concentration is 1mg in 0.1 ml. Even while following the protocol, variability in the final 













Several cases of intraocular inflammation have been reported after injection of very high doses of 
intracameral cefuroxime.30 Six patients received 40-50 mg of intracameral cefuroxime instead of 1 
mg because of a dilution error. The patients had moderate anterior chamber inflammation, 
extensive macular oedema, diffuse leakage on fluorescein angiogram and abnormal 
electroretinograms (ERG) indicating alteration of the rod photoreceptors. The patients were 
observed without surgical intervention and the final visual outcome was satisfactory in all cases. 
Modifications in central corneal thickness (CCT) and endothelial cell density (ECD) were similar to 
those observed after uneventful phacoemulsification. Long-term retinal function was not evaluated 
though. 
 
Severe cystoid macular oedema with subretinal fluid accumulation has been reported in two 
patients who received 2mg of cefuroxime in 0.1 ml.31 The oedema occurred on day one after the 
surgery. Cystoid macular oedema typically takes 4 to 12 weeks to develop after cataract surgery, and 
the rapidity of onset of oedema in these two patients, increased the probability that it was due to 
the cefuroxime.  
 
Despite the risk of dilution error, cefuroxime even at doses 40-50 times the recommended dose, 
appeared to have no long-term side effects, but that needs to be confirmed with repeated ERG 
testing. The fact that ECD did not appear to be adversely affected indicates that cefuroxime may be 
less toxic to endothelial cells than indicated by in vitro testing.26  
 
 
FURTHER STUDIES ADVOCATING THE USE OF CEFUROXIME 
 
In 2002 the Department of Ophthalmology at St. Eriks Hospital in Sweden published data from a 
retrospective observational study to compare the rate of endophthalmitis from 1990 to 1995 with 
the rate from 1996 to 2000. Cefuroxime was added to the prophylactic program in January 1996 
because the rate of endophthalmitis was considerably higher than reported rates in North America.9 
 
The rate of endophthalmitis dropped from 0.26% to 0.06%.  (from 89 cases in 34 102 operations to 
20 in 32 180 operations). Coagulase-negative staphylococci, streptococci with the exception of 
enterococci, and S aureus virtually disappeared as causative organisms, indicating that cefuroxime is 













A cause for concern was the fact that cefuroxime was less effective against gram negative bacteria 
and enterococci, indicating that there were shortcomings in the antibacterial spectrum of 
cefuroxime. 
 
Since the publication of the ESCRS study results, numerous other studies have followed, showing 
similar results, with a significant decrease in the incidence of endophthalmitis after adding 
cefuroxime to the prophylactic regime. 
 
In Dar es Salaam, Tanzania, the rate has dropped from 0.24% (12 cases in 5000 operations) to 0% 
(none in 21 000 operations).32 The University Hospital of Getafe in Madrid, Spain showed a reduction 
of 0.5% to 0.11% (five cases) where two of the five did not receive cefuroxime due to a penicillin 
allergy and S epidermidis was isolated from the vitrectomy cassette in both cases.33 
 
 Another unit in Madrid, University Hospital Fundación Alcorcón, reported a reduction of 0.59% to 
0.043%.34 In the group that did not receive cefuroxime, the leading causative organisms were 
coagulase-negative staphylococci (S epidermidis) and S aureus. 
 
A retrospective analysis performed by Yu-Wai-Man P, et al, at the University of Sunderland, United 
Kingdom, showed that intracameral cefuroxime resulted in a three-fold reduction in the rate of 
presumed infectious endophthalmitis when compared to subconjunctival cefuroxime.35 The 
incidence of presumed infectious endophthalmitis was 0.046% in the intracameral group and 0.139% 
in the subconjunctival group which was statistically significant. 
 
In all the studies discussed above, a significant reduction in the rate of endophthalmitis is apparent. 
These are all retrospective observational studies, with all the limitations associated with these 
studies, but the results are strikingly similar and cannot be ignored. 
 
 
DID THE USE OF INTRACAMERAL CEFUROXIME INCREASE AFTER THE PUBLICATION OF THE ESCRS 
STUDY RESULTS? 
 
In 2005, before the publication of the results of the ESCRS study, a large survey of 800 consultant 
cataract surgeons in the United Kingdom showed that 66.4% gave subconjunctival cefuroxime and 
10% gave intracameral cefuroxime.36 Vancomycin was used as a bolus by 3.6% of surgeons and as an 













In June 2008, approximately 250 consultant members of the United Kingdom and Ireland Society of 
Cataract and Refractive Surgeons (UKISCRS) were surveyed with a 39% response rate (98 
members).37 The main criticisms of the ESCRS study were the lack of a subconjunctival cefuroxime 
treatment arm (68%), the high control group rate of endophthalmitis (13%), statistical analysis 
queries (13%) and the choice of cefuroxime (6%).  
 
More surgeons used intracameral antibiotics, with 55% using intracameral cefuroxime and 5% using 
vancomycin. Thirty-seven percent of respondents used no intracameral antibiotic at all. Of the 
surgeons using cefuroxime, 48% switched after publication of the ESCRS trial. The increased rate of 
intracameral cefuroxime use in this study might not be a true reflection of current practices in the 
U.K. because of the small number of surgeons surveyed. (98 of approximately 900 cataract surgeons 
in the U.K.) 
 
The perioperative patterns of prophylaxis in Canada were published in 2007, after a survey was 
conducted between November 2004 and January 2005.38 Of the 800 ophthalmologists surveyed, 239 
responded (30% response rate) of which 216 performed cataract surgery. Only 15% of surgeons used 
intracameral antibiotics with vancomycin the most commonly used intracameral antibiotic (87%). 
Postoperative topical antibiotics were used by 97% with moxifloxacin being the most common 
postoperative topical antibiotic (30%). 
 
Subsequently to the ESCRS study, a retrospective analysis of the incidence of endophthalmitis in a 
high volume unit in Canada, showed that none of the 25 surgeons operating in that unit, used 
intracameral antibiotics, and 76% used fourth-generation fluoroquinolones in the post-operative 
period.39 The incidence of endophthalmitis was 0.043% in this unit (six of 13931 surgeries). The 
authors concluded that very low rates of endophthalmitis can be achieved without the routine use 
of intracameral antibiotics and that the use of it would introduce other potential risks such as toxic 
anterior segment syndrome. 
 
 
ALTERNATIVES TO INTRACAMERAL CEFUROXIME 
 
The most commonly used prophylactic agents in the United States and Canada are fourth-generation 
fluoroquinolones, such as moxifloxacin (Vigamox) and gatifloxacin (Zymar), of which moxifloxacin is 
used most often. Moxifloxacin has also been used intracamerally, and studies evaluating 
intracameral moxifloxacin showed it to be safe in terms of endothelial cell counts, corneal 













Moxifloxacin is commercially available as a self-preserved ophthalmic solution and it eliminates the 
risks of using an antibiotic that needs to be prepared prior to surgery. 
 
Recent reports of emerging antibiotic resistance to fluoroquinolones are worrying.42,43 Resistance is 
also being reported in the fourth-generation fluoroquinolones. As much as 85% of methicillin-
resistant S Aureus isolates are resistant to ophthalmic fluoroquinolones, including gatifloxacin and 
moxifloxacin. The important question is whether ophthalmologists are contributing to the emerging 





The European Society of Cataract and Refractive Surgeons (ESCRS) recognized the need to 
investigate the use of antimicrobial prophylaxis. According to the findings of a prospective 
randomized study published in 2007, the absence of an intracameral cefuroxime prophylactic 
antibiotic was associated with a 4.92-fold increase in the risk for total postoperative 
endophthalmitis.12 This is the first prophylactic anti-infective regimen to be proven effective by a 
prospective randomized controlled study. Believing the results conclusive, the study was terminated 
prematurely by the investigators, and the routine use of intracameral cefuroxime was 
recommended. 
 
In January 2007 an online survey was conducted among the approximately 4000 members of the 
American Society of Cataract and Refractive Surgeons (ASCRS). Surprisingly 77% of surgeons still did 
not use intracameral cefuroxime and did not plan to use it in the near future.17 Almost 90% of the 
surgeons felt that further study was needed and 45% were concerned about the risk involved. 
 
Further studies have confirmed the efficacy of intracameral cefuroxime in preventing 
endophthalmitis, without any significant adverse effects.10,25,33,44 Dilution error and ocular toxicity 
after high doses of cefuroxime however, have been reported.30   
 
Ophthalmologists need to standardize the prophylaxis of endophthalmitis and it has to be evidence 
based. Ophthalmologists should try to avoid using the same antibiotics for treatment and 
prophylaxis, as this could cause further resistance, especially vancomycin which is used to treat 













In middle and low income countries cefuroxime is much more cost-effective than moxifloxacin, and 
for that reason remains the more logical choice. The lack of a commercially available preparation 
seems to be a major issue amongst ophthalmologists not using cefuroxime. Unfortunately the 
manufacturing of such a product would most certainly increase the cost of using cefuroxime 
significantly and would make it less attractive in middle and low income countries. 
 
Dilution errors remain a problem, but if a strict protocol is followed and the nurses and doctors 
responsible for the preparation of the intracameral antibiotics receive adequate training, the risk 
should be negligible.       
  
The most effective mode of prophylaxis will probably change as bacterial resistance patterns 
emerge, and the studies of the last five years might become irrelevant. It remains the clinician’s 
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ABSTRACT 
PURPOSE:  Did the introduction of intracameral cefuroxime during cataract surgery reduce the rate 
of endophthalmitis in a hospital in South Africa? Did the results of the ESCRS study influence South 
African ophthalmologists’ practice, and what percentage use intracameral cefuroxime? 
SETTING: Groote Schuur Hospital, Cape Town, South Africa. 
DESIGN: Before-after retrospective case series, cross sectional survey 
METHODS:  Data were collected over a six year period, examining all reported cases of 
endophthalmitis following cataract surgery and comparing the data for the three years prior to the 
introduction of cefuroxime, to the three years after the introduction of cefuroxime. A questionnaire, 
with an enclosed self-addressed envelope, was mailed to all South African ophthalmologists. 
RESULTS:  There was a significant reduction in the rate of endophthalmitis following the introduction 
of intracameral cefuroxime, from 0.55% to 0.08% (p=0.0013). Of the 23 cases prior to cefuroxime, 16 
eyes were culture positive (69.6%), 13 were gram positive cocci and three were gram positive bacilli. 
There were no culture positive eyes in the cefuroxime group. The response rate to the questionnaire 
was 74%.  Of the 245 respondents, 74 ophthalmologists (30%) reported using cefuroxime as part of 
their prophylactic regime. 
CONCLUSION:  Prophylaxis w th intracameral cefuroxime is effective in our setting. South African 





Endophthalmitis remains one of the most devastating complications following cataract surgery, and 
the prognosis and successful treatment depends on timely and appropriate management, as 
demonstrated in the Endophthalmitis Vitrectomy Study.1 The treatment of endophthalmitis can be 
extremely problematic in low and middle income countries where patients often present late and 













The optimal regime for endophthalmitis prophylaxis remains a controversial issue. Endophthalmitis 
fortunately is a rare occurrence but this makes it difficult to conduct adequately powered studies.2,3  
The incidence of presumed infectious endophthalmitis is low, with reported rates of 0.05% to 0.36% 
and an overall estimate of 0.13%.4-6 
 
In the past, the only evidence based method of endophthalmitis prophylaxis shown to be effective, 
was the use of povidone-iodine 5% in the conjunctival sac before surgery.7 
  
Many different techniques are being used without reliable scientific evidence. The incidence of 
endophthalmitis is so low, that a very large study is needed to provide statistically significant 
evidence to detect a reduction in the incidence of endophthalmitis.2,3 
 
Most surgeons use antibiotic prophylaxis. Some use vancomycin either in the irrigation fluid or by 
intracameral injection. This practice is not recommended because vancomycin is reserved for the 
treatment of methicillin-resistant Staphylococcus aureus (MRSA) endophthalmitis and other MRSA 
infections.8 Both the American Academy of Ophthalmology and the Center for Disease Control and 
Prevention in the USA advised against its use in cataract surgery.  
 
The European Society of Cataract and Refractive Surgeons (ESCRS) recognized the need to 
investigate the use of antimicrobial prophylaxis. According to the findings of a prospective 
randomized study published in 2007, the absence of an intracameral cefuroxime prophylactic 
antibiotic was associated with a 4.92-fold increase in the risk for total postoperative 
endophthalmitis.9 This is the first prophylactic anti-infective regimen to be proven effective by a 
prospective randomized controlled study. Believing the results conclusive, the study was terminated 
prematurely by the investigators, and the routine use of intracameral cefuroxime was 
recommended. 
 
In January 2007 an online survey was conducted among the approximately 4000 members of the 
American Society of Cataract and Refractive Surgeons (ASCRS). Surprisingly 77% of surgeons still did 
not use intracameral cefuroxime and did not plan to use it in the near future.10 Almost 90% of the 
surgeons felt that further study was needed and 45% were concerned about the risk involved. 
 
Further studies have confirmed the efficacy of intracameral cefuroxime in preventing 
endophthalmitis, without any significant adverse effects.11-14 Dilution error and ocular toxicity after 













Following the publication of the results of the ESCRS study, intraoperative intracameral cefuroxime 
was introduced as our standard practice at Groote Schuur Hospital in August 2006. Apart from 
patients with known cefuroxime hypersensitivity, all patients routinely receive 1mg of intracameral 
cefuroxime, injected into the anterior chamber at the end of their surgery. 
 
The objective of this study was to evaluate whether the routine use of intracameral cefuroxime 
resulted in a decrease in the prevalence of endophthalmitis in our setting and if the results of the 
ESCRS study influenced the trend of endophthalmitis prophylaxis among South African 




The study received ethical approval from the Research Ethics Committee of the University of Cape 
Town. The study designs consisted of a descriptive and analytical retrospective case series and a              
cross sectional survey of all South African ophthalmologists during 2010 and 2011. 
 
 All ophthalmologists in South Africa were surveyed, using a questionnaire that was sent via mail to 
their registered address. They were requested to return the questionnaire in an enclosed self-
addressed envelope. The questionnaire was publicised at a national meeting of the Ophthalmology 
Society of South Africa. 
 
For the case series data were collected from the records of patients who had cataract surgery in the 
36 month period before the introduction of cefuroxime prophylaxis and compared to the data of 
patients who had cataract surgery in the 36 month period after the introduction of cefuroxime 
prophylaxis. 
 
For each period, the following data were collected: number of cataract surgeries performed; number 
of patients admitted for presumed endophthalmitis; whether the patient with suspected 
endophthalmitis  received cefuroxime; number of culture proven cases of endophthalmitis;  the 
organism cultured; number of patients receiving intravitreal antibiotics; number of patients 
requiring pars plana vitrectomy; visual outcome post endophthalmitis treatment; associated possible 
risk factors in endophthalmitis cases, including gender, age, race, type of surgery, surgeon 














The number of cataract surgeries performed in the six year period from August 2003 until July 2009 
was obtained from theatre records. The admission records of endophthalmitis cases were obtained 
from the clinicom records, specifying the number of admissions for code H44.0 (the diagnostic code 
for endophthalmitis) between August 2003 and July 2009. A separate data collection form was 
completed for all patients who presented to the ophthalmology ward with suspected 
endophthalmitis after cataract surgery. 
 
Data were analysed using the statistical program Stata Version 9.0. Variables were described using 






At the time of the survey there were 330 ophthalmologists in South Africa of which 245 responded 
to the questionnaire resulting in a 74.2% response rate. The ophthalmologists were asked to 
document their perioperative antibiotic practices and all modalities of antibiotic administration 
used. Table 1 summarises the results of the questionnaire. 
 Table 1: Primary method of endophthalmitis prophylaxis used by South African ophthalmologists 
Primary method of 
prophylaxis 
number of surgeons percentage 
   







Irrigation fluid vancomycin 






Topical moxifloxacin  























 245 100% 
 
152 surgeons used only one agent as prophylaxis. The remaining 93 surgeons used two or more 
agents. The two agents used most frequently as second agent were topical moxifloxacin                    













There were23 of 4219 (0.55%) cases of endophthalmitis in the pre-cefuroxime group and 3 of 3971 
(0.08%) cases of endophthalmitis in the cefuroxime group. The reduction in the proportion of cases 
of endophthalmitis following the introduction of cefuroxime was significant (p=0.0013). The relative 
risk reduction was 86% (95% CI 53.9-95.8%), the absolute risk reduction was 0.47% (95% CI 0.2-
0.7%), and the number needed to treat was 212 (95% CI 133-419). 
 
Table 2: Results from endophthalmitis cases  
Clinical endophthalmitis Organism cultured Surgical complications Surgeon 
experience 
Final visual acuity 
 PRIOR TO CEFUROXIME    
Patient 1 None Torn rhexis, PC intact Consultant 6/24 
Patient 2 Strep pneumoniae None Registrar      NPL 
Patient 3  Strep pneumoniae None Consultant      NPL 
Patient 4 None None Consultant 6/5 
Patient 5  Strep pneumoniae None Registrar      NPL 
Patient 6 Staph epidermidis None Registrar 6/18 
Patient 7 Bacillus species None Registrar 6/9 
Patient 8 None None Registrar 6/9 
Patient 9 Bacillus species None Registrar 6/12 
Patient 10 Staph epidermidis None Registrar 6/6 
Patient 11 Staph aureus None Registrar      NPL 
Patient 12 Bacillus cereus Zonular dehiscence Registrar      NPL 
Patient 13 Staph epidermidis Unstable ant. chamber Registrar      HM 
Patient 14 Staph aureus None Consultant 6/18 
Patient 15 Staph epidermidis None Consultant      NPL 
Patient 16 None None Registrar 6/12 
Patient 17 Micrococcus species  PC tear, vitreous loss Registrar      NPL 
Patient 18 Streptococcus mitis PC tear, vitreous loss Registrar      HM 
Patient 19 None None Registrar      NPL 
Patient 20 None None Consultant 6/5 
Patient 21 Staph epidermidis Incomplete rhexis Consultant      CF 
Patient 22 Staph epidermidis None Registrar 6/9 
Patient 23 None No clinical notes Unknown 6/18 
     
 POST CEFUROXIME    
Patient 1 None None Registrar 6/9 
Patient 2 None None Registrar 6/9 
Patient 3  None None Registrar      NPL 
  Posterior capsule(PC)  Count fingers(CF) 
Hand movement(HM) 















Table 2 shows the culture results in the endophthalmitis cases. Of the 23 cases prior to cefuroxime, 
16 eyes were culture positive (69.6%) and seven were culture negative. All three cases of 
endophthalmitis after introduction of cefuroxime were culture negative. Of 16 culture positive eyes, 
13 were gram positive cocci and three were gram positive bacilli. Infection was caused by 
Staphylococcus epidermidis in six eyes, Staphylococcus aureus in two eyes, Streptococcus pneumonia 
in three eyes, Streptococcus mitis in one eye, Micrococcus species in one eye and Bacillus species in 
three eyes. Absence of cefuroxime is more likely to result in culture positive result (69.6% of cases 
with p=0.046) 
  
Possible risk factors for worse visual outcome were analysed. There was no statistically significant 
difference in final visual acuity (V/A) between the cefuroxime and non-cefuroxime groups (Fisher 
exact p=1.00). There was no statistically significant difference in final V/A between the different 
organisms cultured (Fisher exact p=0.812), although notably all three patients with Streptococcus 
pneumonia had a final V/A of No Perception of Light (NPL).  There was a statistically significant 
difference in final V/A between cases with and without surgical complications. Patients with surgical 
complications ended with Count Fingers vision or worse, except for one patient with 6/24 vision, 




South African ophthalmologists use a wide variety of antibiotic prophylactic measures. Cefuroxime is 
the preferred method, with 30% of ophthalmologists using it as prophylaxis, but topical moxifloxacin 
and intracameral moxifloxacin is also used by a large proportion of ophthalmologists. The number of 
ophthalmologists (14.7%) using vancomycin in the irrigation fluid as the primary method of 
prophylaxis, is cause for concern, because we should try to avoid using the same antibiotic for 
treatment and prophylaxis, as this could cause further resistance, especially vancomycin which is 
used to treat methicillin-resistant Staphylococcus aureus. 
 
In middle to low income countries cefuroxime is much more cost-effective than moxifloxacin, and 
for that reason remains the logical choice. The lack of a commercially available preparation seems to 
be a major issue amongst ophthalmologists not using cefuroxime. Unfortunately the manufacturing 
of such a product would most certainly increase the cost of using cefuroxime and would make it less 
attractive in middle to low income countries. 
 
Many surgeons fear drug hypersensitivity in penicillin allergic patients. In a study conducted in 
Sweden, 5813 patients undergoing cataract surgery were screened and 233 had skin prick testing 
with cefuroxime if they reported possible hypersensitivity to β-lactam antibiotics. Only three tests 












cefuroxime instilled in the anterior chamber after being pre-treated with oral antihistamine. No 
adverse effects were observed. Hypersensitivity should constitute no limitation to its use as 
endophthalmitis prophylaxis. 
 
Our study has a number of weaknesses. Part of this study was a retrospective case series and non-
controlled, which makes it a less adequately powered study than a prospective randomised 
controlled trial would be, however the results were the same as previously reported by similar 
studies.11,16,17,18 Only 74% of ophthalmologists responded to our survey therefore the 
endophthalmitis prophylaxis patterns may not be a true reflection of the current practices used. We 
did not ask what the reasons might be for not using intracameral cefuroxime, and this information 
would be useful. 
 
At our institution the endophthalmitis rate was reduced from 0.55% to 0.08% after the introduction 
of cefuroxime. The number to treat is fairly large, with 212 patients receiving cefuroxime to prevent 
one case of endophthalmitis, but the cost of treatment needed for endophthalmitis and its 
associated morbidity would easily negate the cost of cefuroxime for 212 patients. 
 
The organisms cultured in the pre-cefuroxime group confirmed that cefuroxime is a very effective 
choice for prophylaxis. Cefuroxime is less effective against gram negative bacteria, but no gram 
negative organisms were cultured in our study. Surgical complications during surgery increased the 
risk of poor visual outcome in patients who developed endophthalmitis in the pre-cefuroxime group. 
The prognosis for visual recovery is very poor in this group of patients, and endophthalmitis must be 
prevented as far as possible. 
  
The most effective mode of prophylaxis will probably change as bacterial resistance patterns 
emerge, and the studies of the last five years might become irrelevant. It remains the clinician’s 
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